DIEBOLD NIXDORF INC (DBD) Fundamental Analysis & Valuation

NYSE:DBD • US2536512021

Current stock price

74.37 USD
+1.89 (+2.61%)
Last:

This DBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. DBD Profitability Analysis

1.1 Basic Checks

  • In the past year DBD was profitable.
  • DBD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: DBD reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • DBD has a better Return On Assets (2.45%) than 67.57% of its industry peers.
  • Looking at the Return On Equity, with a value of 8.60%, DBD is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
  • DBD has a Return On Invested Capital of 10.65%. This is in the better half of the industry: DBD outperforms 75.68% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 15.96%.
  • The 3 year average ROIC (8.32%) for DBD is below the current ROIC(10.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROIC 10.65%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

1.3 Margins

  • DBD has a Profit Margin of 2.49%. This is in the better half of the industry: DBD outperforms 67.57% of its industry peers.
  • DBD has a better Operating Margin (8.79%) than 78.38% of its industry peers.
  • In the last couple of years the Operating Margin of DBD has grown nicely.
  • DBD's Gross Margin of 26.37% is in line compared to the rest of the industry. DBD outperforms 45.95% of its industry peers.
  • In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
Industry RankSector Rank
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DBD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DBD is creating some value.
  • The number of shares outstanding for DBD has been reduced compared to 1 year ago.
  • Compared to 5 years ago, DBD has less shares outstanding
  • DBD has a better debt/assets ratio than last year.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 1.99 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.99, DBD is in line with its industry, outperforming 56.76% of the companies in the same industry.
  • DBD has a debt to FCF ratio of 3.59. This is a good value and a sign of high solvency as DBD would need 3.59 years to pay back of all of its debts.
  • DBD's Debt to FCF ratio of 3.59 is fine compared to the rest of the industry. DBD outperforms 70.27% of its industry peers.
  • A Debt/Equity ratio of 0.85 indicates that DBD is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.85, DBD perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Altman-Z 1.99
ROIC/WACC1.36
WACC7.84%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that DBD should not have too much problems paying its short term obligations.
  • DBD's Current ratio of 1.30 is in line compared to the rest of the industry. DBD outperforms 45.95% of its industry peers.
  • A Quick Ratio of 0.92 indicates that DBD may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.92, DBD perfoms like the industry average, outperforming 51.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DBD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.93% over the past year.
  • The Earnings Per Share has been growing by 48.24% on average over the past years. This is a very strong growth
  • Looking at the last year, DBD shows a small growth in Revenue. The Revenue has grown by 1.46% in the last year.
  • Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -0.50% on average per year.
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.66% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 2.76% on average over the next years.
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. DBD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.67, the valuation of DBD can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 86.49% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.71. DBD is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 13.42, the valuation of DBD can be described as correct.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 70.27% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, DBD is valued a bit cheaper.
Industry RankSector Rank
PE 13.67
Fwd PE 13.42
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 94.59% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, DBD is valued cheaply inside the industry as 83.78% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.93
EV/EBITDA 6.64
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)7.4
PEG (5Y)0.28
EPS Next 2Y11.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBD Dividend Analysis

5.1 Amount

  • No dividends for DBD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBD Fundamentals: All Metrics, Ratios and Statistics

DIEBOLD NIXDORF INC

NYSE:DBD (3/16/2026, 10:00:54 AM)

74.37

+1.89 (+2.61%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12
Earnings (Next)05-05
Inst Owners104.32%
Inst Owner Change-2.29%
Ins Owners1.83%
Ins Owner Change0.97%
Market Cap2.62B
Revenue(TTM)3.81B
Net Income(TTM)94.60M
Analysts82.86
Price Target98.6 (32.58%)
Short Float %2.51%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.23%
Min EPS beat(2)46.39%
Max EPS beat(2)68.07%
EPS beat(4)4
Avg EPS beat(4)43.94%
Min EPS beat(4)1.76%
Max EPS beat(4)68.07%
EPS beat(8)6
Avg EPS beat(8)66.37%
EPS beat(12)8
Avg EPS beat(12)-75.33%
EPS beat(16)10
Avg EPS beat(16)-76.24%
Revenue beat(2)0
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-1.85%
Max Revenue beat(2)-0.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.09%
Min Revenue beat(4)-1.85%
Max Revenue beat(4)3.02%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.54%
Revenue beat(16)4
Avg Revenue beat(16)-1.85%
PT rev (1m)22.36%
PT rev (3m)22.36%
EPS NQ rev (1m)-5.6%
EPS NQ rev (3m)-5.6%
EPS NY rev (1m)12.72%
EPS NY rev (3m)12.72%
Revenue NQ rev (1m)-2.07%
Revenue NQ rev (3m)-2.07%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 13.67
Fwd PE 13.42
P/S 0.69
P/FCF 9.93
P/OCF 8.7
P/B 2.38
P/tB N/A
EV/EBITDA 6.64
EPS(TTM)5.44
EY7.31%
EPS(NY)5.54
Fwd EY7.45%
FCF(TTM)7.49
FCFY10.07%
OCF(TTM)8.55
OCFY11.5%
SpS108.21
BVpS31.27
TBVpS-9.52
PEG (NY)7.4
PEG (5Y)0.28
Graham Number61.87
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROCE 13.48%
ROIC 10.65%
ROICexc 12.68%
ROICexgc 40.66%
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
FCFM 6.92%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
ROICexc(3y)9.91%
ROICexc(5y)8.22%
ROICexgc(3y)32.13%
ROICexgc(5y)32.22%
ROCE(3y)10.53%
ROCE(5y)8.51%
ROICexgc growth 3Y61.28%
ROICexgc growth 5Y10.41%
ROICexc growth 3Y110.53%
ROICexc growth 5Y16.22%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Debt/EBITDA 2.03
Cap/Depr 29.33%
Cap/Sales 0.98%
Interest Coverage 5.66
Cash Conversion 65.07%
Profit Quality 278.33%
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z 1.99
F-Score7
WACC7.84%
ROIC/WACC1.36
Cap/Depr(3y)20.25%
Cap/Depr(5y)18.73%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.5%
EBIT growth 3Y159.26%
EBIT growth 5Y21.84%
EBIT Next Year56.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y99.77%
FCF growth 3YN/A
FCF growth 5Y25.37%
OCF growth 1Y101.54%
OCF growth 3YN/A
OCF growth 5Y21.73%

DIEBOLD NIXDORF INC / DBD Fundamental Analysis FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 5 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.